Vaccine Code Set Update Publication Date: June 18, 2024
The individual filenames included in this distribution contain the publication date (20240618)
Release Notes: This release includes updates to all regular vaccine code set files. Vaccine Information Statement (VIS) related code files are not included.
General Note Regarding this Release: Codes with “Last Update” dates after May 19, 2024, and before June 13, 2024, reflect the changes and additions in this release. This release includes the following code set updates:
1. Avian Influenza H5N8 Vaccine Codes
While the risk to human health remains low, the U.S. Government and partners are increasing its preparedness posture for H5 vaccine, including developing and manufacturing avian influenza human vaccines. To help prepare for a situation in which avian influenza human vaccines are authorized/approved and recommended, three new CVX codes have been added. These CVX codes are mapped to a new vaccine group to differentiate these codes from those used for the former national stockpile H5N1 vaccines.
In the event an avian influenza human vaccine is authorized/approved, these CVX codes will subsequently be associated to new product NDCs, manufacturer MVX code, and a VIS code for an Emergency Use Authorization (EUA) Recipient and Caregiver Fact Sheet, if required. The American Medical Association (AMA) will also be developing a new current procedural terminology (CPT) code to accommodate such need.
If products are not authorized/approved by the FDA, the CVX and any other related codes added to the vaccine code sets (except the new vaccine group) will be retired.
2. Respiratory Syncytial Virus (RSV) Vaccine
A new mRNA RSV vaccine from Moderna has been approved by the FDA. For this vaccine, a new CVX code has been added, new NDCs have been added, a new product tradename record has been added and code associations have been added from CVX to NDC, MVX, and CPT. A VIS has not yet been associated to the new CVX code, pending review.
In addition, the RSV vaccine Fall 2023 table on CDC’s IIS Data Code Sets website has been updated. This new vaccine has been added with a notation that it is a new Fall 2024 vaccine. This table will be further updated once the RSV products from all manufacturers are verified for the 2024 Fall season. You can access here Fall Season Respiratory Vaccine Codes | CDC Fall Season Respiratory Vaccine Codes | CDC
3. Non-US CVX Code Added
A new code has been added to record the fractional dose inactivated polio vaccines (fIPV) administered outside of the U.S.
4. Other Code Set Updates
- Cholera Vaccine (Vaxchora) NDCs. New NDCs listed under Bavarian Nordic.
- Product Table Updates. New Product table entry added associating Vaxchora (Cholera vaccine) to the Bavarian Nordic MVX and the Product table entry associating Vaxchora to the MVX for Emergent Health has been retired.
- Other NDC Updates. NDCs retired and other miscellaneous field changes.
Vaccine Code Set Updates – Details
- Avian Influenza H5N8 Vaccine Codes
New Vaccine Group: A new Vaccine Group has been added, “FLU-Avian-H5”. The uncertain formulation CVX code that should be utilized with this vaccine group when recording a historic vaccine administration will be the new unspecified vaccine group CVX code 323.
Starting in June 2024, new H5N1 or other H5 strains of avian flu vaccine products and associated CVX codes will be associated to the new vaccine group.
Note: The prior existing avian influenza Vaccine Group “H5N1 flu” is currently only associated to CVX codes for H5N1 vaccine products from the national stockpile that were retired in 2018.
- New CVX Codes: The following table identifies the three new avian influenza CVX codes. As noted, these CVX codes are associated to new Vaccine Group “FLU-Avian-H5”.
CVX | Long Description | Short Description | CVX Note | CVX Status |
|---|
321 | Influenza-avian, H5N8, viral-vector, monovalent, injectable, preservative free | Influenza-avian, H5N8 monovalent, PF | Novel Bird Flu H5N8 Vaccine 2024 | Active |
|---|
322 | Influenza-avian, H5N8, viral-vector, monovalent, injectable, contains preservative | Influenza-avian, H5N8, monovalent, preservative | Novel Bird Flu H5N8 Vaccine 2024 | Active |
|---|
323 | Influenza-avian, H5, unspecified formulation | Influenza-avian, H5, unspecified formulation | Unspecified code H5xx vaccines to be used when specific formulation is unknown - for vaccines administered starting 2024 | Inactive |
|---|
- RSV Vaccine
A new mRNA RSV Vaccine has been added to the code sets. Codes added for the new product mRESVIA include the following:
- New CVX code below associated to Vaccine Group “RSV”.
CVX | Long Description | Short Description | CVX Note | CVX Status |
|---|
326 | Respiratory syncytial virus (RSV), mRNA, injectable, preservative free | RSV, mRNA, injectable, PF | mRNA RSV vaccine 2024 | Active |
|---|
- New Product Tradename to CVX/MVX. A New Product tradename record has been added for “mRESVIA”. The following table shows the new product record entries and the associated CVX and MVX codes.
CDC Product Tradename Added | Product Status | CVX Code | MVX Code | MVX Manufacturer |
|---|
mRESVIA | Active | 326 | MED | Moderna |
|---|
- New NDCs and Crosswalk. Two new NDC pairs have been added and mapped to CVX, MVX, and CPT Codes.
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Short Description | MVX Code | CPT Code | CPT Description |
|---|
mRESVIA | Moderna US, INC. | 80777-0345-90 | 80777-0345-01 | 326 | RSV, mRNA, injectable, PF | MOD | 90683 | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use |
|---|
mRESVIA | Moderna US, INC. | 80777-0345-96 | 80777-0345-01 |
|---|
- Non-US CVX Code Added. A new code has been added to record the fractional-dose inactivated polio vaccines (fIPV) administered outside of the U.S. The following new CVX code has been added to Vaccine Group “POLIO”.
CVX | Long Description | Short Description | CVX Note | CVX Status |
|---|
324 | Poliovirus, inactivated, fractional-dose (fIPV) | Poliovirus, inactivated, fractional-dose (fIPV) | Non-US polio vaccine administered since 2016 | Non-US |
|---|
- Other Code Set Updates
- Cholera Vaccine (Vaxchora) NDCs. The New NDCs are listed under Bavarian Nordic and associated to MVX “BN”. Note that during the transition to Bavarian Nordic there still remain active Vaxchora NDCs listed under FDA licensing to Emergent which retain the MVX code “PAX”.
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Short Description | MVX Code |
|---|
Vaxchora | Bavarian Nordic A/S | 50632-0015-02 | 50632-0015-02 | 174 | cholera, live attenuated | BN |
|---|
- Product Table Updates. A new Product table entry has been added for the association to Bavarian Nordic and the prior Product table entry has been retired in anticipation of full transition of Vaxchora product to Bavarian Nordic manufacturing.
CDC Product Tradename Added | Product Status | CVX Code | MVX Code | MVX Manufacturer |
|---|
Vaxchora | Active | 174 | BN | Bavarian Nordic A/S |
|---|
CDC Product Tradename Retired | Product Status | CVX Code | MVX Code | MVX Manufacturer |
|---|
VAXCHORA | Inactive | 174 | PAX | Emergent Travel Health, Inc (Formerly PaxVax) |
|---|
- Other NDC Updates. NDCs retired and other field changes; the following table identifies NDC pairs where there have been other updates or field changes affecting the date of last update.
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Short Description | MVX Code | Start Date | End Date |
|---|
1. NDCs Retired – End Date Added |
|---|
Menactra | Sanofi Pasteur Inc. | 49281-0589-05 | 49281-0589-58 | 114 | meningococcal MCV4P | PMC | 1/14/2005 | 10/1/2022 |
|---|
2. NDC Other Changes in FDA NDC Listing File: Updated date of last update but without visible change to CDC vaccine code structured outputs |
|---|
Arexvy | GlaxoSmithKline Biologicals SA | 58160-0848-11 | 58160-0723-03 | | | | | |
|---|
CYFENDUS | Emergent Product Development Gaithersburg Inc. | 71665-0001-02 | 71665-0001-01 | | | | | |
|---|
Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 59267-4315-02 | 59267-4315-01 | | | | | |
|---|
3. NDCs Removed/Excluded from all NDC files and crosswalks: The following COVID-19 NDCs were published ahead of FDA EUA, but never authorized (*) |
|---|
ASTRAZENECA COVID-19 VACCINE | AstraZeneca Pharmaceuticals LP | 00310-1222-15 | 00310-1222-10 | | | | | |
|---|
(*) CDC does not typically remove records from files that have been previously published. The records remain in our database and are available with an exclude attribute and reason if using the Viewpoint Browser or the Web Services method of code set access.
